Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock Has Consensus Target Price of $155.56

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) has earned an average rating of “Moderate Buy” from the fifteen analysts that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, thirteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $155.56.

A number of research analysts have recently commented on the company. Stifel Nicolaus upped their target price on Mirum Pharmaceuticals from $136.00 to $156.00 and gave the company a “buy” rating in a research note on Wednesday, October 14th. Citigroup raised their price target on Mirum Pharmaceuticals from $184.00 to $194.00 and gave the stock a “buy” rating in a research note on Wednesday, November 11th. Weiss Ratings cut Mirum Pharmaceuticals from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, October 22nd. Leerink Partners cut their price objective on Mirum Pharmaceuticals from $154.00 to $140.00 and set an “outperform” rating on the stock in a research report on Thursday, November 5th. Finally, UBS Group set a $137.00 price objective on Mirum Pharmaceuticals in a research report on Thursday, August 27th.

Check Out Our Latest Research Report on MIRM

Insider Activity

In related news, Director Laura Brege sold 14,167 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Wednesday, November 11th. The shares were sold at an average price of $94.21, for a total value of $1,334,673.07. Following the completion of the sale, the director directly owned 15,703 shares in the company, valued at $1,479,379.63. This trade represents a 47.43% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Jolanda Howe sold 658 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $100.00, for a total value of $65,800.00. Following the sale, the senior vice president owned 616 shares in the company, valued at approximately $61,600. The trade was a 51.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 64,825 shares of company stock worth $6,160,873. Insiders own 8.32% of the company’s stock.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Integrated Wealth Concepts LLC purchased a new position in Mirum Pharmaceuticals during the second quarter worth about $27,000. Quantbot Technologies LP purchased a new stake in shares of Mirum Pharmaceuticals in the 2nd quarter valued at approximately $44,000. State of Wyoming purchased a new stake in shares of Mirum Pharmaceuticals in the 2nd quarter valued at approximately $52,000. Fifth Third Bancorp purchased a new stake in shares of Mirum Pharmaceuticals in the 1st quarter valued at approximately $56,000. Finally, Allworth Financial LP lifted its holdings in shares of Mirum Pharmaceuticals by 19.5% in the 3rd quarter. Allworth Financial LP now owns 827 shares of the company’s stock worth $71,000 after acquiring an additional 135 shares during the last quarter.

Mirum Pharmaceuticals Price Performance

NASDAQ MIRM opened at $96.13 on Friday. The stock has a market capitalization of $6.28 billion, a price-to-earnings ratio of -6.21 and a beta of 0.75. Mirum Pharmaceuticals has a 1-year low of $63.23 and a 1-year high of $130.00. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.07 and a quick ratio of 1.98. The business’s fifty day moving average price is $88.19 and its 200-day moving average price is $98.17.

Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.38). The company had revenue of $185.72 million for the quarter, compared to the consensus estimate of $178.07 million. Mirum Pharmaceuticals had a negative net margin of 134.75% and a negative return on equity of 97.25%. The business’s revenue for the quarter was up 39.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.05 EPS. On average, equities analysts predict that Mirum Pharmaceuticals will post -1.47 earnings per share for the current year.

About Mirum Pharmaceuticals

(Get Free Report)

Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare liver and other serious diseases. Founded in 2018, the company works on therapies for conditions with limited treatment options. Its commercial products include Livmarli (maralixibat), an oral treatment for cholestatic pruritus associated with Alagille syndrome and, in the United States, progressive familial intrahepatic cholestasis. Mirum also markets Cholbam (cholic acid) for certain bile acid synthesis disorders and Chenodal (chenodiol) for cerebrotendinous xanthomatosis.

See Also

Analyst Recommendations for Mirum Pharmaceuticals (NASDAQ:MIRM)

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.